Company intelligence / Profile preview

Modiblast

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Modiblast has published preclinical in vivo data and initial human data validating its therapeutic strategy in AML. Their approach shows potential to restore neutrophil and thrombocyte counts in heavily pre-treated patients.

Therapeutic areas: Oncology
Modalities: In vivo cell reprogrammingFixed-dose combination therapy
Industry: Biotech

Drug pipeline

1 asset

MB101

Pre-clinical

Indications: Acute myeloid leukemia

Beyond the preview

Go deeper on Modiblast.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modiblast.

Explore the full profile